Product image of Jeligo (Linagliptin) supplied by GNH India

Jeligo

Active Ingredient:
Linagliptin
Origin:
EU

Jeligo (Linagliptin)

Linagliptin, the active ingredient in Jeligo, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established logistics and regulatory expertise to ensure reliable delivery across multiple markets, and consistent quality assurance for patient safety.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jeligo (linagliptin) is used within the antidiabetic drug class to manage blood glucose levels in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves glycaemic control as part of a comprehensive treatment plan.
  • Adjunct therapy: used together with other antidiabetic agents to achieve target HbA1c.
  • Combination with metformin: provides enhanced glucose lowering when both agents are prescribed.
  • Renal impairment: can be used without dose adjustment in patients with mild to moderate renal dysfunction.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which results in increased levels of the incretin hormones GLP‑1 and GIP. Elevated incretins enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, thereby lowering post‑prandial and fasting blood glucose concentrations.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient pain in the head region.
  • Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhea.
  • Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: such as rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: rare skin disorder characterized by blistering lesions.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Renal function monitoring: assess baseline and periodic kidney function.
  • Hepatic assessment: evaluate liver enzymes in patients with liver disease.
  • Pancreatitis vigilance: educate patients to report persistent abdominal pain.
  • Hypoglycemia risk: review concomitant use of insulin or sulfonylureas.
  • Patient education: instruct on recognizing signs of allergic reactions.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Linagliptin may interact with other medicines; review the following.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure.
  • Combination with insulin or sulfonylureas: increased risk of hypoglycemia.
  • Strong P‑gp inhibitors (e.g., itraconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor electrolytes and blood pressure.

  • ACE inhibitors: observe for potential additive blood pressure effects.
  • Warfarin: check INR values periodically for any alteration.

Frequently Asked Questions

Jeligo contains linagliptin, a DPP‑4 inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet, exercise, and possibly other antidiabetic agents.

Linagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, leading to lower blood sugar levels.

The appropriate dose of Jeligo is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Jeligo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Jeligo (linagliptin) shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its once‑daily dosing and minimal renal excretion, allowing use without dose adjustment in most patients with renal impairment, unlike some alternatives that require dose changes.

Jeligo should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or extreme temperatures.

Jeligo is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and do not crush or chew it.

The most serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or breathing difficulties.

Jeligo is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for individuals with a history of pancreatitis, severe liver disease, or those taking medications that may cause significant drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT